For professionals
CMT2C for researchers: what is known, what is not, and where the data are
If you work on TRPV4, on axonal neuropathies or on rare-disease trial design, this page is the short route into what this site holds: a read and annotated library of 271 papers, the open questions a patient community would most like answered, the cohorts and studies that exist, and a standing invitation to talk to us.
CMT2C is caused by gain-of-function variants in TRPV4 [10]; blocking the channel rescued symptomatic mice [15], and the first TRPV4 inhibitor, STAR-0871 (previously ABS-0871), has completed a Phase 1a study with a patient study planned for 2027 [318]. The largest clinical dataset is the 68-person TRPV4 registry [3]; two natural history studies are recruiting [101] [52]. What is missing most: longitudinal data in adults, outcome measures that capture bulbar and respiratory involvement, and an explanation of the variability.
Where this comes from. I live with CMT2C and I am not a scientist. The literature review on this site gathers the published experts’ work in one place; it was built with AI help and a stated method, and every claim is cited so you can check it. The analyses are best read as an indexed reading guide, not as a systematic review. Corrections are welcome and are credited.
The literature, read and indexed
The research section holds 271 papers found by systematic searching of PubMed, Europe PMC and the preprint servers, ranked by relevance to CMT2C and then by what their evidence rests on. 106 are analyzed in depth, each with: what the authors did, who or what was studied, key findings, the authors' own conclusion, how each paper decided that a relative was unaffected, the opportunities it leaves for further research, and three reading levels. Every analysis says whether it was written from the full text, from detailed reading notes or from the abstract only. The method page gives the search strings, the ranking rules and the analysis prompt.
- Papers explained: the 106 analyses, with search, an author filter, topic filters (genetics, mechanism, breathing and voice, skeleton, hearing, penetrance, natural history, imaging and more) and ordering by relevance, date or first author.
- All papers: every paper in five relevance groups, with short notes on the 165 that are not analyzed in depth.
- What the research says: the synthesis, including the sections “Unaffected” relatives: who was actually checked? and What nobody knows yet.
- TRPV4 variants: the well-documented neuromuscular variants with their classifications, and worked examples of variants still uncertain.
- Sources: the full numbered list, with DOIs and PMIDs.
Sixteen papers in the two most relevant groups have not been read in full because they are paywalled; if you can share a copy, their entries will be upgraded. The list is in the project's open items and I am happy to send it.
Open questions a patient community would like answered
These come out of the synthesis and the registry paper, and they are the questions people with CMT2C ask most. Each is a study someone could design.
- Penetrance. How often does a person who carries a pathogenic TRPV4 variant stay unaffected for life? Reported unaffected relatives were often not examined or nerve-tested, so the published estimates rest on uneven evidence [6]. The site records, paper by paper, how “unaffected” was established.
- Rate of change in adults. Only 13 people in the registry had repeat examinations, so the natural history of adult-onset and adult-phase disease is nearly undescribed [3]. Age predicts severity less well than in CMT2A or CMTX1 [3].
- Variability. Why do some people with a given variant develop vocal fold, respiratory, hearing or skeletal involvement and others with the same variant do not, even within one family [6]? Modifiers, mosaicism and environment are all open.
- Translation. Every result for TRPV4 blockers so far is from cells, flies or mice [15] [26]. Whether blocking the channel helps people, and at what stage, is the question the planned trial will start to answer [318].
- Under-measured features. Bladder symptoms (45% difficulty urinating), sweating and hearing are rarely tested for, so their true frequency is unknown [3]. The same goes for pain (49% arthritic-like) and fatigue.
- Breathing care. Nothing about respiratory management has been studied in CMT2C itself; the site's guidance is borrowed from neuromuscular disease in general [288] [308]. When to start ventilation, and whether early support changes outcomes, is unanswered.
- Surgery and healing. One 2026 case of severe noninfectious wound dehiscence after cavovarus reconstruction raised a question about healing in TRPV4-associated CMT that only a series can answer (Elhaddad et al., 2026).
Cohorts, studies and data
- The TRPV4 registry (Inherited Neuropathies Consortium): 68 people with pathogenic variants, 40 of whom completed a TRPV4-specific questionnaire; cross-sectional with limited longitudinal follow-up; published in Brain in 2025 [3]. The site's symptom tables reproduce its figures.
- Johns Hopkins TRPV4 natural history study, NCT05600764: ages 3 to 80 with a TRPV4 variant, United States and Canada, yearly visits over six years with neurological examination, nerve conduction studies, imaging, voice and vocal fold assessment and functional tests; sponsored by Johns Hopkins with the Muscular Dystrophy Association and Actio Biosciences [101].
- INC 6601: the Inherited Neuropathy Consortium's natural history study of all CMT types, 21 sites in the US, Canada, the UK, Italy and Australia, with a TRPV4-specific survey at enrollment [52].
- Patient registries: GRIN (Hereditary Neuropathy Foundation), free and worldwide, and the CMTA's Patients as Partners in Research, which recruits for surveys, focus groups and listening sessions [54]. How patients join.
- Community material that is not public. The TRPV4 patient group on Facebook holds a decade of first-hand accounts, a 2020 Johns Hopkins Q&A and a 2023 CMTA/Actio focus group recording; none is cited on this site because none is published. If you are designing a study and want to hear from the community, Stephanie Carmody, who runs the group, and I can help. See Work with us.
- Shared trial rules. In August 2026 a coalition of CMT organizations, patients, clinicians and companies (ToPIC), led mainly by the CMT Research Foundation, published shared recommendations on trial design, endpoints, biomarkers and enrollment in the Journal of the Peripheral Nervous System; they cover all CMT types [99].
Outcome measures and biomarkers
The registry authors called for outcome measures that capture non-length-dependent weakness, vocal fold weakness and respiratory involvement, because the standard CMT scales miss them [3]. FDA guidance on natural history studies in rare disease explains how such data decide who to enroll, what to measure and how long to run a trial [91]. Two biomarker projects are under way at Johns Hopkins with CMT Research Foundation funding: a search for a blood biomarker of CMT2C in treated and untreated models (Sullivan and Sumner), and profiling of neurovascular endothelial cells in a CMT2C model (Alevy), building on earlier work on TRPV4 and the blood-nerve barrier [99] [30]. The 2026 Global CMT Research Convention's endpoint session (Fridman, Chrea, Pernice, moderated by McCray) is on the foundation's video platform.
From the patient side, the registry's “most bothersome symptom” answers are a ready-made priority list: speech and breathing problems (22%) and leg weakness (21%) came first [3]. Several people in our community cannot lie flat for imaging or for nerve testing; a protocol that allows for that would be easier for them to join.
Where treatment stands
- STAR-0871 (previously ABS-0871; Setara Biosciences, spun out of Actio Biosciences): an oral small-molecule TRPV4 inhibitor with Rare Pediatric Disease, Orphan Drug and Fast Track designations; the healthy-volunteer part of its Phase 1 study is complete and a Phase 1b study in people with CMT2C (THERON) is planned for 2027 [318] [319]. Setara does not offer expanded access at present [318].
- Preclinical rationale. Gain of function in TRPV4 drives the neuropathy [10]; a blocker gave “a marked phenotypic rescue of symptomatic mutant mice”, acting through endothelial cells and the blood-CNS barrier [15]; mutant TRPV4 disrupts mitochondrial transport through CaMKII-dependent calcium elevation [26]. The mechanism page walks through the structural and cellular literature, including the gain-of-function debate.
- Drugs for other or all CMT types that a CMT2C reader may ask about are sorted on Trials and research into “already open to CMT2” (ignaseclant) and “could work, ask the researchers” (RTX-117, AGT-100216, SARM1 inhibitors, EN001), with the reasoning for each.
What patients told us matters
On 20 October 2026 the FDA held a patient listening session for the CMT2C/TRPV4 community, organized by the CMTA; the FDA's summary is pending [104]. Why ABS-0871 matters sets out, in patients' own words, what a meaningful result would look like: holding steady counts; voice, breath and hands matter more than scores built for the feet; and trials need measures that see the disease we have. If you are writing a patient-focused section of a protocol or a grant, that page and the stories are quotable with attribution.
Work with us
- Recruitment and feedback. I can share a study with the community and collect questions before you finalize a protocol. Stephanie Carmody has run the TRPV4 patient group for more than ten years and knows which families are where.
- Review this site. A clinician's review in October 2026 changed how the research section presents evidence. If you see an error, an over-reading of a paper, or a paper that is missing, write to cmt2cinfo@gmail.com.
- Full texts. The sixteen unread papers are listed in the project's open items; a copy of any of them upgrades its analysis.
- Reuse. The site's text was put together by a patient from published sources and may be quoted with a link. Journal full texts are never stored in the repository.
This page was put together by a patient from published sources and is not peer reviewed. Every statement is referenced to the numbered sources. Last reviewed October 2026.